Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 284

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 284
---
 advisable, and in the best interests of BLAC and its stockholders for reasons listed below: Significant Market Opportunities Recurrent Glioblastoma (rGBM) Market GBM, the most common brain tumor in adults, is usually rapidly fatal and has very limited therapy options. The current standard of care consists of surgery followed by radiation and temozolomide (TMZ). Roche’s Avastin is the only targeted therapy approved for recurrent GBM (US and Japan), which has not demonstrated a survival benefit. GBM patients have an overall survival of between one and two years and median survival of 14.6 months under radiotherapy plus temozolomide treatment. 1 The global GBM treatment market was valued at $5.14 billion in 2020 and is anticipated to reach $10.2 billion by 2030. 2The forecasted market size and growth are limited due to a dearth of treatment options available. Hepatocellular Cancer (HCC) Market Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide. 3OSR Holdings’ research indicates that the prevalence of hepatocellular carcinoma was highest in China, followed by the US and Japan in 2023. The increasing prevalence of HCC is driving hepatocellular carcinoma treatment market growth. According to estimates, more than 1 million people will be affected with hepatocellular carcinoma annually by 2025. 4 Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC, and, since its launch, has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Nexavar’s patent protection in the 7MM market expired in December 2022, and generic sorafenib has entered the market. ____________ 1Stupp, R., et al. (2005). “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.” New England Journal of Medicine, 352(10), 987 -996 2 https: // www.biospace.com / article /glioblastoma -multiforme - treatment-market - size-to -hit-10-2- bn-by -2030 3Villanueva, A. (